N@N

Matt Miksic Maintained (ABT) at Buy with Increased Target to $127 on, Apr 20th, 2023

Matt Miksic of Barclays, Maintained "Abbott Laboratories" (ABT) at Buy with Increased Target from $125 to $127 on, Apr 20th, 2023.

Matt has made no other calls on ABT in the last 4 months.

There are 10 other peers that have a rating on ABT. Out of the 10 peers that are also analyzing ABT, 1 agrees with Matt's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Anthony Petrone of "Mizuho" Maintained at Hold with Increased Target to $110 on, Tuesday, January 24th, 2023

These are the ratings of the 9 analyists that currently disagree with Matt

---

• Ryan Zimmerman of "BTIG" Maintained at Strong Buy with Increased Target to $130 on, Monday, April 17th, 2023
• Lawrence Biegelsen of "Wells Fargo" Maintained at Buy with Decreased Target to $136 on, Monday, April 10th, 2023
• Larry Biegelsen of "Wells Fargo" Maintained at Buy with Decreased Target to $136 on, Wednesday, April 5th, 2023
• Danielle Antalffy of "UBS" Initiated at Strong Buy and Held Target at $117 on, Wednesday, March 29th, 2023
• Lee Hambright of "Bernstein" Maintained at Buy with Increased Target to $132 on, Thursday, January 26th, 2023
• Marie Thibault of "BTIG" Maintained at Strong Buy with Increased Target to $125 on, Thursday, January 26th, 2023
• Rick Wise of "Stifel" Maintained at Strong Buy with Increased Target to $125 on, Thursday, January 26th, 2023
• Mike Polark of "Wolfe Research" Maintained at Sell with Increased Target to $107 on, Wednesday, January 25th, 2023
• Cecilia Furlong of "Morgan Stanley" Maintained at Buy with Increased Target to $133 on, Friday, January 6th, 2023

Contributing Sources

---